Sinunasal malignoma – good survival rate with multimodal therapy in squamous cell- and adenocarcinoma in Münster

Introduction:

Squamous cell carcinoma and adenocarcinoma are among the most common entities of sinunasal malignoma. In most cases, the tumors are aggressive and invade anatomic borders such as the skull base and orbital cavity. Therefore histologic diagnosis leads to a radical tumor treatment.

Methods:

We performed a retrospective evaluation of all patients with sinunasal carcinoma (squamous cell- and adenocarcinoma) from 2004 to 2017 in the Department of otorhinolaryngology treated at the University Hospital Münster.

Results:

In our study, we included 111 patients with carcinoma of the nose- (38, 34,2%) and paranasal cavities (73, 65,8%). 75 patients (67,6%) suffered a squamous cell carcinoma and 36 (32,4%) an adenocarcinoma. At diagnosis, mean age was 60.4 years (range: 29 – 88 years) with a predominantly male collective (73.9% men). 54 carcinoma (48,6%) were classified T1 or T2, 57 carcinoma (51,4%) were in T3 or T4 stadium. 102 patients (91,9%) underwent primary surgery and 60 (54%) of them received an adjuvant treatment. Lymph node metastases were detected in 8 patients (7,2%), 2 patients (1,8%) showed distant metastases at the point of diagnosis and recurrence occurred in 25 patients (22,5%). The mean follow up was 45.3 month (range: 1 – 170 month). The 5-year survival was 89.7% and the progression-free-survival after 5 years was 64.3%. Patients with R1 and R2 status (p = 0.004) and patients with T3 and T4 stadium (p = 0.004) had a significantly worse survival rate.

Conclusion:

A multimodal therapy of squamous cell- and adenocarcinoma of the sinunasal area resulted in a good 5-year survival rate. Especially a R0 resection results in better survival rates.

Publication History

Publication Date:
23 April 2019 (online)